Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajenthen G Ranjan

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Diabetes/Metabolism Research and Reviews|October 22, 2020
Glucagon for hypoglycaemia treatment in type 1 diabetesAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Diabetes, Obesity & Metabolism|March 25, 2025
Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trialAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Diabetologia|April 10, 2023
Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trialChristian Laugesen, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 26, 2019
Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey StudyRikke Tetzschner, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Care|April 27, 2022
Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover StudyChristian Laugesen, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Technology & Therapeutics|January 31, 2022
Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational StudySabine Schade Jacobsen, Eva Hommel, Ajenthen G Ranjan, et al.
Diabetes Technology & Therapeutics|April 2, 2025
Long-Term Glycemic Benefits and User Interaction Insights: Real-World Outcomes of Automated Insulin Delivery Use in a Pediatric PopulationEmilie B Lindkvist, Ajenthen G Ranjan, Kristen Nørgaard, et al.
Diabetes Technology & Therapeutics|July 10, 2026
Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery SystemsAjenthen G Ranjan, Katrine G Tidemand, Jannet Svensson, et al.
BMJ Open Diabetes Research & Care|January 29, 2021
Time spent in hypoglycemia is comparable when the same amount of exercise is performed 5 or 2 days weekly: a randomized crossover study in people with type 1 diabetesIsabelle Isa Kristin Steineck, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Technology & Therapeutics|September 28, 2019
Glucose Sensor Accuracy After Subcutaneous Glucagon Injections Near to Sensor SiteChristian Laugesen, Signe Schmidt, Rikke Tetzschner, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Diabetes/Metabolism Research and Reviews|October 22, 2020
Glucagon for hypoglycaemia treatment in type 1 diabetesAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Diabetes, Obesity & Metabolism|March 25, 2025
Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trialAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Diabetologia|April 10, 2023
Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trialChristian Laugesen, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 26, 2019
Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey StudyRikke Tetzschner, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Care|April 27, 2022
Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover StudyChristian Laugesen, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Technology & Therapeutics|January 31, 2022
Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational StudySabine Schade Jacobsen, Eva Hommel, Ajenthen G Ranjan, et al.
Diabetes Technology & Therapeutics|April 2, 2025
Long-Term Glycemic Benefits and User Interaction Insights: Real-World Outcomes of Automated Insulin Delivery Use in a Pediatric PopulationEmilie B Lindkvist, Ajenthen G Ranjan, Kristen Nørgaard, et al.
Diabetes Technology & Therapeutics|July 10, 2026
Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery SystemsAjenthen G Ranjan, Katrine G Tidemand, Jannet Svensson, et al.
BMJ Open Diabetes Research & Care|January 29, 2021
Time spent in hypoglycemia is comparable when the same amount of exercise is performed 5 or 2 days weekly: a randomized crossover study in people with type 1 diabetesIsabelle Isa Kristin Steineck, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Technology & Therapeutics|September 28, 2019
Glucose Sensor Accuracy After Subcutaneous Glucagon Injections Near to Sensor SiteChristian Laugesen, Signe Schmidt, Rikke Tetzschner, et al.
Pageof 4